Elucidation of the pathogenic mechanism of rhegmatogenous retinal detachment with proliferative vitreoretinopathy by proteomic analysis

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 13, 2012, Pages 8146-8153

  Yu, Jing ^a   Peng, Runsheng ^b   Chen, Hui ^c   Cui, Chen ^c   Ba, Jun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c NANTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 GLYCOPROTEIN; COMPLEMENT; CYTOSKELETON PROTEIN; FETUIN A; HEMOPEXIN; MACROPHAGE ELASTASE; NUCLEAR RECEPTOR COREPRESSOR; PROTEIN P53; THROMBIN; TRANSCRIPTION FACTOR E2F1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE REGULATORY NETWORK; HUMAN; ISOELECTRIC POINT; MALE; MICROTUBULE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMERIZATION; PROTEOMICS; RETINA DETACHMENT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SYNAPSE VESICLE; TANDEM MASS SPECTROMETRY; VITREORETINOPATHY; VITREOUS BODY;

CHROMATOGRAPHY, REVERSE-PHASE; E2F1 TRANSCRIPTION FACTOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EYE PROTEINS; HUMANS; PROTEOME; RETINAL DETACHMENT; TANDEM MASS SPECTROMETRY; TUMOR SUPPRESSOR PROTEIN P53; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 84873332694     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10079     Document Type: Article

References (35)

1. Pastor JC. Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998;43:3-18.
2. Pastor JC, Rodriguez de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002;21:127-144.
3. The Retina Society Terminology Committee. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983;90:121-125.
4. Charteris DG, Sethi CS, Lewis GP, Fisher SK. Proliferative vitreoretinopathy: developments in adjunctive treatment and retinal pathology. Eye. 2002;16:369-374.
5. Haniu H, Komori N, Takemori N, Singh A, Ash JD, Matsumoto H. Proteomic trajectory mapping of biological transformation: application to developmental mouse retina. Proteomics. 2006; 6:3251-3261.
6. Neal RE, Bettelheim FA, Lin C, Winn KC, Garland DL, Zigler JS Jr. Alterations in human vitreous humour following cataract extraction. Exp Eye Res. 2005;80:337-347.
7. Ouchi M, West K, Crabb JW, Kinoshita S, Kamei M. Proteomic analysis of vitreous from diabetic macular edema. Exp Eye Res. 2005;81:176-182.
8. Wu CW, Sauter JL, Johnson PK, Chen CD, Olsen TW. Identification and localization of major soluble vitreous proteins in human ocular tissue. Am J Ophthalmol. 2004; 137:655-661.
9. Yamane K, Minamoto A, Yamashita H, et al. Proteome analysis of human vitreous proteins. Mol Cell Proteomics. 2003;2: 1177-1187.
10. Shitama T, Hayashi H, Noge S, et al. Proteome profiling of vitreoretinal diseases by cluster analysis. Proteomics Clin Appl. 2008;2:1265-1280.
11. Yu J, Liu F, Cui SJ, et al. Vitreous proteomic analysis of proliferative vitreoretinopathy. Proteomics. 2008;8:3667-3678.
12. Schirle M, Heurtier MA, Kuster B. Profiling core proteomes of human cell lines by one-dimensional PAGE and liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics. 2003;2:1297-1305.
13. Ouchi M, West K, Crabb JW, Kinoshita S, Kamei M. Proteomic analysis of vitreous from diabetic macular edema. Exp Eye Res. 2005;81:176-182.
14. Nakanishi T, Koyama R, Ikeda T, Shimizu A. Catalogue of soluble proteins in the human vitreous humor: comparison between diabetic retinopathy and macular hole. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;776:89-100.
15. Grisanti S, Esser P, Weller M, Wiedemann P, Heimann K. Proliferative vitreoretinopathy. Activation of the complement system. Ophthalmologe. 1992;89:50-54.
16. Grisanti S, Wiedemann P, Weller M, Heimann K, Zilles K. The significance of complement in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1991;32:2711-2717.
17. Cashman SM, Desai A, Ramo K, Kumar-Singh R. Expression of complement component 3 (C3) from an adenovirus leads to pathology in the murine retina. Invest Ophthalmol Vis Sci. 2011;52:3436-3645.
18. Chao J, Chao L. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol. 2005;90:291-298.
19. Diamandis EP, Okui A, Mitsui S, et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res. 2002;62:295-300.
20. Zhang Y, Bhat I, Zeng M, et al. Human kallikrein 10, a predictive marker for breast cancer. Biol Chem. 2006;387: 715-721.
21. Chao J, Bledsoe G, Yin H, Chao L. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biol Chem. 2006;387:665-675.
22. Gu B, Zhu WG. Surf the post-translational modification network of p53 regulation. Int J Biol Sci. 2012;8:672-684.
23. Lai D, Visser-Grieve S, Yang X. Tumour suppressor genes in chemotherapeutic drug response. Biosci Rep. 2012;32:361-374.
24. Prykhozhij SV. In the absence of Sonic hedgehog, p53 induces apoptosis and inhibits retinal cell proliferation, cell-cycle exit and differentiation in zebrafish. PLoS One. 2010;5:e13549.
25. Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis. 2012;33:2007-2017.
26. Rothenberg SM, Ellisen LW. The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest. 2012; 122:1951-1957.
27. Desplats P, Spencer B, Crews L, et al. Alpha-synuclein induces alterations in adult neurogenesis in Parkinson disease models via p53-mediated repression of Notch1. J Biol Chem. 2012; 287:31691-31702.
28. Bialopiotrowicz E, Szybinska A, Kuzniewska B, et al. Highly pathogenic Alzheimer's disease presenilin 1 P117R mutation causes a specific increase in p53 and p21 protein levels and cell cycle dysregulation in human lymphocytes. J Alzheimers Dis. 2012;32:397-415.
29. Bhattacharya S, Ray RM, Chaum E, Johnson DA, Johnson LR. Inhibition of Mdm2 sensitizes human retinal pigment epithelial cells to apoptosis. Invest Ophthalmol Vis Sci. 2011;52: 3368-3380.
30. Sharma A, Sharma R, Chaudhary P, et al. 4-Hydroxynonenal induces p53-mediated apoptosis in retinal pigment epithelial cells. Arch Biochem Biophys. 2008;480:85-94.
31. O'Connor JC, Wallace DM, O'Brien CJ, Cotter TG. A novel antioxidant function for the tumor-suppressor gene p53 in the retinal ganglion cell. Invest Ophthalmol Vis Sci. 2008;49: 4237-4244.
32. Ganguly A, Shields CL. Differential gene expression profile of retinoblastoma compared to normal retina. Mol Vis. 2010;16: 1292-1303.
33. Blanchet E, Annicotte JS, Pradelli LA, et al. E2F transcription factor-1 deficiency reduces pathophysiology in the mouse model of Duchenne muscular dystrophy through increased muscle oxidative metabolism. Hum Mol Genet. 2012;21: 3910-3917.
34. Chen D, Pacal M, Wenzel P, Knoepfler PS, Leone G, Bremner R. Division and apoptosis of E2f-deficient retinal progenitors. Nature. 2009;462:925-929.
35. Chen J, Zhu F, Weaks RL, et al. E2F1 promotes the recruitment of DNA repair factors to sites of DNA double-strand breaks. Cell Cycle. 2011;10:1287-1294.